Structure Therapeutics (NASDAQ:GPCR) Stock Rating Upgraded by Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.

A number of other analysts have also recently issued reports on GPCR. Canaccord Genuity Group assumed coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 target price for the company. HC Wainwright cut their price objective on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $110.55.

Structure Therapeutics Stock Performance

GPCR opened at $48.04 on Friday. The stock’s fifty day simple moving average is $46.51 and its 200 day simple moving average is $55.15. Structure Therapeutics has a 1-year low of $15.80 and a 1-year high of $94.90. The stock has a market cap of $3.41 billion, a PE ratio of -55.22 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. Equities analysts forecast that Structure Therapeutics will post -1.64 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its stake in shares of Structure Therapeutics by 25.2% in the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after buying an additional 1,432,797 shares during the period. Avoro Capital Advisors LLC grew its position in Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after buying an additional 1,150,000 shares in the last quarter. Janus Henderson Group PLC increased its stake in Structure Therapeutics by 5.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock worth $258,260,000 after acquiring an additional 264,833 shares during the period. BVF Inc. IL raised its holdings in Structure Therapeutics by 8.6% in the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after acquiring an additional 275,105 shares in the last quarter. Finally, Morgan Stanley raised its holdings in Structure Therapeutics by 261.4% in the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.